UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
|
||
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code:
N/A
(Former name or former address, if changed since last report.)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading |
Name of each exchange | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 | Other Events. |
On May 23, 2022, Kewaunee Scientific Corporation (the “Company”), in consideration for an extension fee, extended by an additional 30 days the period for the purchase from the Company of preferred equity in CAI Investments Medical Products I Parent, LLC, a Delaware limited liability company, pursuant to the previously disclosed sale-leaseback arrangement for the Company’s headquarters and manufacturing facilities located at 2700 West Front Street in Statesville, North Carolina.
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
(Registrant) | ||||||
Kewaunee Scientific Corporation | ||||||
Date: May 27, 2022 | /s/ Donald T. Gardner III | |||||
Donald T. Gardner III Vice President, Finance | ||||||
Chief Financial Officer |
Document and Entity Information |
May 23, 2022 |
---|---|
Cover [Abstract] | |
Entity Registrant Name | KEWAUNEE SCIENTIFIC CORP /DE/ |
Amendment Flag | false |
Entity Central Index Key | 0000055529 |
Document Type | 8-K |
Document Period End Date | May 23, 2022 |
Entity Incorporation State Country Code | DE |
Entity File Number | 0-5286 |
Entity Tax Identification Number | 38-0715562 |
Entity Address, Address Line One | 2700 West Front Street |
Entity Address, City or Town | Statesville |
Entity Address, State or Province | NC |
Entity Address, Postal Zip Code | 28677 |
City Area Code | 704 |
Local Phone Number | 873-7202 |
Security 12b Title | Common Stock, $2.50 par value |
Trading Symbol | KEQU |
Security Exchange Name | NASDAQ |
Written Communications | false |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
Entity Emerging Growth Company | false |
-8?20$3;8T.P
M6BP^0"X99K>]9!:G
+,4(GSJCAT;2=W"&I7-9)
MON!DH>+NN"5^=@/F';9+P;8!OIH+# \>KD&%@1Y;V:[]0)@=,0.ZCK@Q#=B%
M^CRW3ZUMUNIYSA](&!8B$[AFN2FV)8A?I/&7$"#/P@399D4HZO-=B%Y)B&I*=9E\
M%Z4W%J4"L_9WW,V*4MSGTJ*T\?"K%GC($XBX!L0UH1CT^$AZ;6:.4TW$/Q!-
MP:2 KSCH WF0HJ?;R-H08R*JB,=:/(B.048Q-<=@#D) /-PFX:39W*F>4"7D-;\Q
MLYX>JK$9KG<4+\Z%=2"J+Z4#HQ9/VQD\VV'6UST0F [T)+7^%3;5SJDC<7UQ
MG3!LL;UW!IO]#YCJ-)Y+JZBI+Z2B3\OF)^?8C$![U7_1\8V^E*T*Z4!9GBXV?1Y7O-;XAU#U17J6?0OXHV. [PB%
MARR9@:A&^;8L75NM[_HSXE)A^B=)JU^:ED=PA..!
M:TO1G<6[F4]Z G 5;D5-?4D5?5HV%\ZP,3=!Z&C)6<5%PK&NOHR.O5I.[FRR
M3"#*C,6P-9L21<\^CXYU]>5T[-5R